IMMUNOREACT 5: female patients with rectal cancer have better immune editing mechanisms than male patients – a cohort study
Gaya Spolverato, Matteo Fassan, Giulia Capelli, Melania Scarpa, Silvia Negro, Valentina Chiminazzo, Andromachi Kotsafti, Imerio Angriman, Michela Campi, Ottavia De Simoni, Cesare Ruffolo, Astghik Stepanyan, Chiara Vignotto, Federico Scognamiglio, Giulia Becherucci, Giorgio Rivella, Francesco Marchegiani, Luca Facci, Francesca Bergamo, Stefano Brignola, Gianluca Businello, Vincenza Guzzardo, Luca Dal Santo, Roberta Salmaso, Marco Massani, Anna Pozza, Ivana Cataldo, Tommaso Stecca, Angelo Paolo Dei Tos, Vittorina Zagonel, Pierluigi Pilati, Boris Franzato, Antonio Scapinello, Giovanni Pirozzolo, Alfonso Recordare, Roberto Merenda, Giovanni Bordignon, Silvio Guerriero, Chiara Romiti, Giuseppe Portale, Chiara Cipollari, Maurizio Zizzo, Andrea Porzionato, Marco Agostini, Francesco Cavallin, Barbara Di Camillo, Romeo Bardini, Isacco Maretto, Ignazio Castagliuolo, Salvatore Pucciarelli, Marco Scarpa
Abstract
BACKGROUND: Studies evaluating sex differences in colorectal cancer (CRC) tumor microenvironment are limited, and no previous study has focused on rectal cancer patients' constitutive immune surveillance mechanisms. The authors aimed to assess gender-related differences in the immune microenvironment of rectal cancer patients. METHODS: A systematic review and meta-analysis were conducted up to 31 May 2021, including studies focusing on gender-related differences in the CRC tumor microenvironment. Data on the mutational profile of rectal cancer were extracted from the Cancer Genome Atlas (TCGA). A subanalysis of the two IMMUNOREACT trials (NCT04915326 and NCT04917263) was performed, aiming to detect gender-related differences in the immune microenvironment of the healthy mucosa in patients with early (IMMUNOREACT 1 cohort) and locally advanced rectal cancer following neoadjuvant therapy (IMMUNOREACT 2 cohort). In the retrospective IMMUNOREACT 1 cohort (therapy naive), the authors enrolled 442 patients (177 female and 265 male), while in the retrospective IMMUNOREACT 2 cohort (patients who had neoadjuvant therapy), we enrolled 264 patients (80 female and 184 male). In the prospective IMMUNOREACT 1 cohort (therapy naive), the authors enrolled 72 patients (26 female and 46 male), while in the prospective IMMUNOREACT 2 cohort (patients who had neoadjuvant therapy), the authors enrolled 105 patients (42 female and 63 male). RESULTS: Seven studies reported PD-L1 expression in the CRC microenvironment, but no significant difference could be identified between the sexes. In the TGCA series, mutations of SYNE1 and RYR2 were significantly more frequent in male patients with rectal cancer. In the IMMUNOREACT 1 cohort, male patients had a higher expression of epithelial cells expressing HLA class I, while female patients had a higher number of activated CD4+Th1 cells. Female patients in the IMMUNOREACT 2 cohort showed a higher infiltration of epithelial cells expressing CD86 and activated cytotoxic T cells (P=0.01). CONCLUSIONS: Male patients have more frequent oncogene mutations associated with a lower expression of T-cell activation genes. In the healthy mucosa of female patients, more Th1 cells and cytotoxic T cells suggest a potentially better immune response to the tumor. Sex should be considered when defining the treatment strategy for rectal cancer patients or designing prognostic scores.